In conclusion, our findings revealed that SPARC, increased in CD patients and colitis mice, resulted in intestinal barrier damage by directly interacting with OTUD4, and activating the MYD88/NF‐κB/MLCK/MLC2 pathway. Here, MYD88 is linked to colitis.